IMMUNOHISTOCHEMICAL PROFILE OF BREAST CARCINOMA IN UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA
Keywords:
Immunohistochemistry, estrogen receptor(ER), progesterone receptor (PR), human epidermal receptor 2(HER2)
Abstract
Background: Breast cancer is the commonest cancer in the female. Immunohistochemistry of breast cancer hormone receptor (ER and PR) and Her2 are very useful tools for assessing the tumor cells behavior and making choice of chemotherapy.
Aims and Objective: The study aimed to describe the immunohistochemical profiles of breast carcinoma at University of Calabar Teaching Hospital (UCTH), Calabar.
Method: This is a descriptive study of immunohistochemistry of breast carcinoma in UCTH using archival paraffin-embedded blocks of breast cancer tissue. The records of cases diagnosed as breast cancer in a five year period (2010-2014) in the department of Histopathology of UCTH are stained immunohistochemically for Oestrogen receptor(ER), Progesterone receptor(PR) and Human epidermal growth factor receptor 2(Her2). The demographic variables and receptor status were collated and analyzed. The status is related to the histopathologic characteristics of tumor size, histologic grade, and histologic subtypes. The findings were presented in tables and charts and statistical significance of variables tested.
Result: One hundred and forty-seven (147) cases of breast cancer samples were analyzed. The mean age at diagnosis was 46.31+/-12.75 years old. The age ranged from 21-80 years old, the modal and median ages were 40 and 45 years respectively. Sixty-four percent (64%) were estrogen receptor positive. Progesterone receptor positive was 40.14% and Her2 positive was 21.09%.
Conclusion: The majority of the breast cancer is estrogen receptor positive but progesterone receptor and Her2 receptor negative.
Downloads
Download data is not yet available.
References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer Base No.11[internet] Lyon, France: International Agency for Research on Cancer, 2013.
2. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumour characteristics and prognosis: a prospective cohort of breast cancer patients. Breast cancer res. 2007,9(1):R6.
3. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population differences in breast cancer: Survey in indigenous African women reveals over representation of triplenegative breast cancer. J Clin Oncol 2009; 27:4515-21.
4. Ohehe-Yeboah M, Adjei E. Breast cancer in Kumasi, Ghana. Ghana Med J 2012; 46(1):8-13.
5. Tesfamariam A and Roy I. Molecular Biology of breast cancer in the Horn of Africa: Case series-A pilot study of breast cancer from Eritrea. ISRN Pathology 2013; Article ID787495:01-07.
6. Adjei EK, Owusu-Afriye O, Awuah B, Stalsberg H. Hormone receptor and Her 2 expression in breast cancer in subsahara Africa. A comparative study of biopsies from Ghana and Norway. Breast J 2014; 20(3):308-11.
7. Mbonde MP, Amir H, Akslen LA, Kitinya JN. Expression of estrogen and progesterone receptors, ki67, p53 and BCL-2 proteins, CathepsinD, Urokinase plasminogen activator and Urokinase plasminogen activator receptor in carcinomas of the female breast in an Africa population. East Afri Med J 2001;78(7):360-65.
8. Bird PA, Hill AG, Houssami N. Poor hormonal receptor expression in east Africa breast cancer: Evidence of a biologically different disease? Ann Surg Oncol 2008; 15(7):1983-88.
9. Satti MB. Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: A 9 years study at Princess Noorah Oncology Centre, Saudi Arabia. Histopathology 2011; 59:537-42.
10. Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE. Immunohistochemical and molecular subtypes of breast cancer in Nigeria.
Breast Cancer Res. And Treat 2008; 110(1):183-88.
11. Adebamowo CA, Ogundiran T, Akang E. Epidemiology of Triple negative breast cancer in Nigeria women. J ClinOncol 2006; 24:10504.
12. Ogundiran TO, Ezeome ER. Epidemiology, clinical presentation, and management of advance Breast Cancer in Nigeria. In the proceeding of Society of Oncology and Cancer Research of Nigeria (SOCRON) 2008 conference, pp1-42.
13. Makanjuola SBL, Ayodele SD, Obafunwa JO Oludara MA, Popoola AO. Breast cancer receptor status assessment and clinicopathological association in Nigerian women: A retrospective analysis. J Cancer Res Ther 2014; 2:122-27.
14. Gukas ID, Jennings BA, Mandong BM, Igun GO, Girling AC, Manasseh AN, et al. Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afri J Med 2005;24(3):209-13.
15. Adeniji KA, Huo D, Khramtsov A, Zhang C Olopade OI. Molecular profiles of breast cancer in Ilorin, Nigeria. 2010 ASCO Annual meeting. J ClinOncol 2010; 28(15s):abstr1602.
16. Ugiagbe EE, Olu-Eddo AN, Obaseki DE. Immunohistochemical detection of HER2/neu over-expression in breast carcinoma in Nigeria: a 5-year retrospective study. Niger J Clin Pract 2011; 14(3):332-37.
17. Titiloye NA, Omoniyi-Esan GO, Adisa AO, Komolafe AO, Afolabi OT, Adelusola KA. Breast cancer in Nigeria Cohort: Histopathology, Immunohistochemical profile, and Survival. Postgraduate Medical Journal of Ghana 2013; 2 (2):83-87.
18. Gukas ID, Girling AC, Mandong BM, Prime W, Jennings BA, Leinster SJ. A comparison of Clinicopathological Features and Molecular Markers in British and igerian Women with Breast
19. Stewart BW, Kleihues P. World Cancer Report 2003. Published by International Agency for Research on Cancer (IARC) press, Lyon 2003. ISBN9283204115.
20. Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Mobus V, et al. 13th St Gallen International Breast Cancer Conference 2013: Primary Therapy of Early breast cancer. Evidence, controversies, consensus- the opinion of a German Team of Experts (Zurich 2013). Breast care 2013;8(3):221-29.
21. Jackisch C, Harbeck N, Huober J, Von Minckwitz G, Gerber B, Kreipe HH, et al. 14th St Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer: Evidence, controversies, consensusOpinion Expressed by German Team of Experts. Breast Care 2015; 10(3):211-19.
22. Rauh C, Gass P, Heusinger K, Haeberle L, Jud SM, Hein A, et al. Association of Molecular subtypes with breast cancer risk factors: a case-only analysis. Eur J
Cancer Prev, 2015; 24(6):484-90.
23. Ebughe GA, Ekanem IA, Omoronyin OE, Nnoli MA, Nwagbara VJ, Udosen JE, et al. Age-specific incidence of breast cancer in Calabar, Nigeria. International Journal of Tropical Disease and Health. 2016, 16(4):1-12.
24. Nwafor CC, Keshinro SO. Pattern of hormones receptor and Human epidermal growth factor 2 status in subsahara breast cancer cases: Private Practice experience. Nigerian Journal of Clinical Practice 2015; 18(4):553-58.
25. Forae GD, Nwachokor FN, Igbe AP. Histopathologic profile of breast cancer in an African population. Ann Med Health Sci Res 2014; 4(3):369-73.
26. Ihekwaba FN. Breast Cancer in Nigerian Women. Br J surg 1992; 79(8):771-75.
27. Galukande M, Wabinga H, Mirembe F, Karamagi C, Asea A. Molecular breast cancer subtypes prevalence in an indigenous subsahara African population. The Pan African Medical Journal 2014; 17:249.
28. Anyanwu SNC. Temporal Trends in breast cancer presentation in the third world. J Exp Clin Cancer Res. 2008; 27(1)17.
29. Irianiwati W, Dwianingsih EK, Triningsih E, Utoro T, Soeripto. Clinicopathologic features of Indonesian breast cancer with different Molecular subtypes. Asian Pac J Cancer Prev. 2014; 15(15): 6109-13.
30. Abdulrahman GO Jr, Rahman GA. Epidemiology of breast cancer in Europe and Africa. J Cancer Epidemiol 2012; Article ID 915610:01-05.
31. Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of Breast Cancer in Asian Women. World J Surg 2007; 31 (5):1031-40.
32. Fregene A, Newman LA. Breast cancer in Sub-Saharan Africa: how does it relate to breast cancer in African– American women. Cancer 2005;103(8):1540-50.
33. Anim JT. Breast Cancer in Sub-Saharan African Women. Afr J Med Sci 1993; 22(1):5-10.
34. Adebamowo CA, Ajayi OO. Breast Cancer in Nigeria. West Afr J Med 2000; 19(3):179-91.
35. Adebamowo CA, Adekunle OO. Case controlled study of the epidemiological risk factor for breast cancer in Nigeria. Br J Surg 1999; 86(5):665-68.
36. Anyanwu SN. Breast cancer in eastern Nigeria: a ten year review. West Afr J Med 2000; 19(2):120-25.
37. Ikpatt OF, Kuopio T, Ndoma-Egba R, Collan Y. Breast Cancer in Nigeria and Finland: epidemiological, clinical and histological comparison. Anticancer Res 2002; 22(5):3005-12.
38. Ebughe GA, Ugare GU, Nnoli MA, Bassey IA, Nwagbara VJ, Udosen JE, et al. Histological Type and Tumour Grade in Nigerian breast cancer: relationship to
menarche, family history of breast cancer, parity, age at first birth and age at menopause. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)2013; 7(5):58-63.
39. Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, et al. Biology of breast cancer in Nigeria women: a pilot study. Ann Afr Med 2012; 11(3):169-75.
40. Dauda AM, Misauno MA, Ojo EO. Histopathological Types of Breast Cancer in Gombe, North Eastern Nigeria: a seven year review. Afr J Reprod. Health. 2011; 15(1):107-09.
41. Nggada HA, Yawe KD, AbdulazeezJ, Khalil MA. Breast cancer burden in Maiduguri, North Eastern Nigeria. Breast J 2008; 14(3):284-86.
42. Udo-Affah GU, Eru EM, Kalu C, Uruakpa KC, Inyang JI. The prevalence of breast cancer in University of Calabar Teaching Hospital (UCTH) and General Hospital Calabar (GHC) from 2006 to 2010. IOSR Journal of Nursing and Health Science (IOSR-JNHS) 2014; 3(5):08-10.
43. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes and survival in the Carolina Breast Cancer study. JAMA. 2006; 295(21):2492-502.
44. Javaria I, Mohamma A, Alam AS, Ghadah MA, Bandar NA. Hormone receptor status of breast cancer in different age groups, lymph node status, histologic type and tumour grade, an experience at King Fahad Medical City, Riyadh. Pak J Surg 2014; 30(4):296-300.
45. Saleh F and Abdeen S. Pathobiological features of breast tumours in the state of Kuwait: a comprehensive analysis. Journal of carcinogenesis 2007; 6:12:01-12.
2. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumour characteristics and prognosis: a prospective cohort of breast cancer patients. Breast cancer res. 2007,9(1):R6.
3. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population differences in breast cancer: Survey in indigenous African women reveals over representation of triplenegative breast cancer. J Clin Oncol 2009; 27:4515-21.
4. Ohehe-Yeboah M, Adjei E. Breast cancer in Kumasi, Ghana. Ghana Med J 2012; 46(1):8-13.
5. Tesfamariam A and Roy I. Molecular Biology of breast cancer in the Horn of Africa: Case series-A pilot study of breast cancer from Eritrea. ISRN Pathology 2013; Article ID787495:01-07.
6. Adjei EK, Owusu-Afriye O, Awuah B, Stalsberg H. Hormone receptor and Her 2 expression in breast cancer in subsahara Africa. A comparative study of biopsies from Ghana and Norway. Breast J 2014; 20(3):308-11.
7. Mbonde MP, Amir H, Akslen LA, Kitinya JN. Expression of estrogen and progesterone receptors, ki67, p53 and BCL-2 proteins, CathepsinD, Urokinase plasminogen activator and Urokinase plasminogen activator receptor in carcinomas of the female breast in an Africa population. East Afri Med J 2001;78(7):360-65.
8. Bird PA, Hill AG, Houssami N. Poor hormonal receptor expression in east Africa breast cancer: Evidence of a biologically different disease? Ann Surg Oncol 2008; 15(7):1983-88.
9. Satti MB. Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: A 9 years study at Princess Noorah Oncology Centre, Saudi Arabia. Histopathology 2011; 59:537-42.
10. Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE. Immunohistochemical and molecular subtypes of breast cancer in Nigeria.
Breast Cancer Res. And Treat 2008; 110(1):183-88.
11. Adebamowo CA, Ogundiran T, Akang E. Epidemiology of Triple negative breast cancer in Nigeria women. J ClinOncol 2006; 24:10504.
12. Ogundiran TO, Ezeome ER. Epidemiology, clinical presentation, and management of advance Breast Cancer in Nigeria. In the proceeding of Society of Oncology and Cancer Research of Nigeria (SOCRON) 2008 conference, pp1-42.
13. Makanjuola SBL, Ayodele SD, Obafunwa JO Oludara MA, Popoola AO. Breast cancer receptor status assessment and clinicopathological association in Nigerian women: A retrospective analysis. J Cancer Res Ther 2014; 2:122-27.
14. Gukas ID, Jennings BA, Mandong BM, Igun GO, Girling AC, Manasseh AN, et al. Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afri J Med 2005;24(3):209-13.
15. Adeniji KA, Huo D, Khramtsov A, Zhang C Olopade OI. Molecular profiles of breast cancer in Ilorin, Nigeria. 2010 ASCO Annual meeting. J ClinOncol 2010; 28(15s):abstr1602.
16. Ugiagbe EE, Olu-Eddo AN, Obaseki DE. Immunohistochemical detection of HER2/neu over-expression in breast carcinoma in Nigeria: a 5-year retrospective study. Niger J Clin Pract 2011; 14(3):332-37.
17. Titiloye NA, Omoniyi-Esan GO, Adisa AO, Komolafe AO, Afolabi OT, Adelusola KA. Breast cancer in Nigeria Cohort: Histopathology, Immunohistochemical profile, and Survival. Postgraduate Medical Journal of Ghana 2013; 2 (2):83-87.
18. Gukas ID, Girling AC, Mandong BM, Prime W, Jennings BA, Leinster SJ. A comparison of Clinicopathological Features and Molecular Markers in British and igerian Women with Breast
19. Stewart BW, Kleihues P. World Cancer Report 2003. Published by International Agency for Research on Cancer (IARC) press, Lyon 2003. ISBN9283204115.
20. Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, Mobus V, et al. 13th St Gallen International Breast Cancer Conference 2013: Primary Therapy of Early breast cancer. Evidence, controversies, consensus- the opinion of a German Team of Experts (Zurich 2013). Breast care 2013;8(3):221-29.
21. Jackisch C, Harbeck N, Huober J, Von Minckwitz G, Gerber B, Kreipe HH, et al. 14th St Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer: Evidence, controversies, consensusOpinion Expressed by German Team of Experts. Breast Care 2015; 10(3):211-19.
22. Rauh C, Gass P, Heusinger K, Haeberle L, Jud SM, Hein A, et al. Association of Molecular subtypes with breast cancer risk factors: a case-only analysis. Eur J
Cancer Prev, 2015; 24(6):484-90.
23. Ebughe GA, Ekanem IA, Omoronyin OE, Nnoli MA, Nwagbara VJ, Udosen JE, et al. Age-specific incidence of breast cancer in Calabar, Nigeria. International Journal of Tropical Disease and Health. 2016, 16(4):1-12.
24. Nwafor CC, Keshinro SO. Pattern of hormones receptor and Human epidermal growth factor 2 status in subsahara breast cancer cases: Private Practice experience. Nigerian Journal of Clinical Practice 2015; 18(4):553-58.
25. Forae GD, Nwachokor FN, Igbe AP. Histopathologic profile of breast cancer in an African population. Ann Med Health Sci Res 2014; 4(3):369-73.
26. Ihekwaba FN. Breast Cancer in Nigerian Women. Br J surg 1992; 79(8):771-75.
27. Galukande M, Wabinga H, Mirembe F, Karamagi C, Asea A. Molecular breast cancer subtypes prevalence in an indigenous subsahara African population. The Pan African Medical Journal 2014; 17:249.
28. Anyanwu SNC. Temporal Trends in breast cancer presentation in the third world. J Exp Clin Cancer Res. 2008; 27(1)17.
29. Irianiwati W, Dwianingsih EK, Triningsih E, Utoro T, Soeripto. Clinicopathologic features of Indonesian breast cancer with different Molecular subtypes. Asian Pac J Cancer Prev. 2014; 15(15): 6109-13.
30. Abdulrahman GO Jr, Rahman GA. Epidemiology of breast cancer in Europe and Africa. J Cancer Epidemiol 2012; Article ID 915610:01-05.
31. Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of Breast Cancer in Asian Women. World J Surg 2007; 31 (5):1031-40.
32. Fregene A, Newman LA. Breast cancer in Sub-Saharan Africa: how does it relate to breast cancer in African– American women. Cancer 2005;103(8):1540-50.
33. Anim JT. Breast Cancer in Sub-Saharan African Women. Afr J Med Sci 1993; 22(1):5-10.
34. Adebamowo CA, Ajayi OO. Breast Cancer in Nigeria. West Afr J Med 2000; 19(3):179-91.
35. Adebamowo CA, Adekunle OO. Case controlled study of the epidemiological risk factor for breast cancer in Nigeria. Br J Surg 1999; 86(5):665-68.
36. Anyanwu SN. Breast cancer in eastern Nigeria: a ten year review. West Afr J Med 2000; 19(2):120-25.
37. Ikpatt OF, Kuopio T, Ndoma-Egba R, Collan Y. Breast Cancer in Nigeria and Finland: epidemiological, clinical and histological comparison. Anticancer Res 2002; 22(5):3005-12.
38. Ebughe GA, Ugare GU, Nnoli MA, Bassey IA, Nwagbara VJ, Udosen JE, et al. Histological Type and Tumour Grade in Nigerian breast cancer: relationship to
menarche, family history of breast cancer, parity, age at first birth and age at menopause. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)2013; 7(5):58-63.
39. Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, et al. Biology of breast cancer in Nigeria women: a pilot study. Ann Afr Med 2012; 11(3):169-75.
40. Dauda AM, Misauno MA, Ojo EO. Histopathological Types of Breast Cancer in Gombe, North Eastern Nigeria: a seven year review. Afr J Reprod. Health. 2011; 15(1):107-09.
41. Nggada HA, Yawe KD, AbdulazeezJ, Khalil MA. Breast cancer burden in Maiduguri, North Eastern Nigeria. Breast J 2008; 14(3):284-86.
42. Udo-Affah GU, Eru EM, Kalu C, Uruakpa KC, Inyang JI. The prevalence of breast cancer in University of Calabar Teaching Hospital (UCTH) and General Hospital Calabar (GHC) from 2006 to 2010. IOSR Journal of Nursing and Health Science (IOSR-JNHS) 2014; 3(5):08-10.
43. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes and survival in the Carolina Breast Cancer study. JAMA. 2006; 295(21):2492-502.
44. Javaria I, Mohamma A, Alam AS, Ghadah MA, Bandar NA. Hormone receptor status of breast cancer in different age groups, lymph node status, histologic type and tumour grade, an experience at King Fahad Medical City, Riyadh. Pak J Surg 2014; 30(4):296-300.
45. Saleh F and Abdeen S. Pathobiological features of breast tumours in the state of Kuwait: a comprehensive analysis. Journal of carcinogenesis 2007; 6:12:01-12.
How to Cite
1.
Kenneth A Omoruyi, Martins A Nnoli, Godwin A Ebughe, Godstime I Irabor, Zulu C Okoligwe, Samuel O Ejike. IMMUNOHISTOCHEMICAL PROFILE OF BREAST CARCINOMA IN UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. Med. res. chronicles [Internet]. 1 [cited 2024Dec.22];5(01):57-0. Available from: https://medrech.com/index.php/medrech/article/view/289
Section
Original Research Article
